Achieving coronary plaque regression: a decades-long battle against coronary artery disease

References

• Roth GA, Mensah GA, Johnson CO, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: update From the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982–3021.
   PubMed Web of Science ®Google Scholar
• Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol. 1988;12(1):56–62.
   PubMed Web of Science ®Google Scholar
• Hadamitzky M, Achenbach S, Al-Mallah M, et al. Optimized prognostic score for coronary computed tomographic angiography: results from the CONFIRM registry (COronary CT Angiography EvaluatioN For Clinical Outcomes: an InteRnational Multicenter Registry). J Am Coll Cardiol. 2013;62(5):468–476.
   PubMedGoogle Scholar
• Naoum C, Berman DS, Ahmadi A, et al. Predictive Value of Age- and Sex-Specific Nomograms of Global Plaque Burden on Coronary Computed Tomography Angiography for Major Cardiac Events. Circ Cardiovasc Imaging. 2017;10(3). DOI:https://doi.org/10.1161/CIRCIMAGI896NG.116.004.
   Google Scholar
• Ferencik M, Mayrhofer T, Bittner DO, et al. Use of High-Risk Coronary Atherosclerotic Plaque Detection for Risk Stratification of Patients With Stable Chest Pain: a Secondary Analysis of the PROMISE Randomized Clinical Trial. JAMA Cardiol. 2018;3(2):144–152.
   PubMed Web of Science ®Google Scholar
• Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: executive Summary: a Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. CIR.0000000000001030.
   Google Scholar
• Khalil MF, Wagner WD, Goldberg IJ. Molecular Interactions Leading to Lipoprotein Retention and the Initiation of Atherosclerosis. Arteriosclerosis. Thrombosis Vasc Biol. 2004;24(12):2211–2218.
   PubMedGoogle Scholar
• Chait A, Wight TN. Interaction of native and modified low-density lipoproteins with extracellular matrix. Curr Opin Lipidol. 2000;11(5):457–463.
   PubMedGoogle Scholar
• Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. Nature reviews. Immunology. 2010;10(1):36–46.
   PubMedGoogle Scholar
• Tabas I, Williams KJ, Borén J. Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis. Circulation. 2007;116(16):1832–1844.
   PubMed Web of Science ®Google Scholar
• Hansson GK. Immune Mechanisms in Atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21(12):1876–1890.
   PubMed Web of Science ®Google Scholar
• Davignon J, Ganz P. Role of Endothelial Dysfunction in Atherosclerosis. Circulation. 2004;109(23_suppl_1):III-27-III–32.
   Google Scholar
• Swirski FK, Libby P, Aikawa E, et al. Ly-6C hi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest. 2007;117(1):195–205.
   PubMed Web of Science ®Google Scholar
• Tacke F, Alvarez D, Kaplan TJ, et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest. 2007;117(1):185–194.
   PubMed Web of Science ®Google Scholar
• Geng Y-J, Libby P. Progression of Atheroma. Arterioscler Thromb Vasc Biol. 2002;22(9):1370–1380.
   PubMedGoogle Scholar
• Llodrá J, Angeli V, Liu J, et al. Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc Natl Acad Sci U S A. 2004;101(32):11779.
   PubMedGoogle Scholar
• Virmani R, Kolodgie FD, Burke AP, et al. Lessons From Sudden Coronary Death. Arterioscler Thromb Vasc Biol. 2000;20(5):1262–1275.
   PubMed Web of Science ®Google Scholar
• Burke AP, Kolodgie FD, Farb A, et al. Healed Plaque Ruptures and Sudden Coronary Death. Circulation. 2001;103(7):934–940.
   PubMedGoogle Scholar
• Shioi A, Ikari Y. Plaque Calcification During Atherosclerosis Progression and Regression. J Atheroscler Thromb. 2018;25(4):294–303.
   PubMed Web of Science ®Google Scholar
• Andrews J, Psaltis PJ, Bartolo BAD, et al. Coronary arterial calcification: a review of mechanisms, promoters and imaging. Trends Cardiovasc Med. 2018;28(8):491–501.
   PubMed Web of Science ®Google Scholar
• St Clair RW. Atherosclerosis regression in animal models: current concepts of cellular and biochemical mechanisms. Prog Cardiovasc Dis. 1983;26(2):109–132.
   PubMedGoogle Scholar
• Lee S-E, Chang H-J, Sung JM, et al. Effects of Statins on Coronary Atherosclerotic Plaques. JACC Cardiovasc Imaging. 2018;11(10):1475–1484.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary AtherosclerosisA Randomized Controlled Trial. JAMA. 2004;291(9):1071–1080.
   PubMed Web of Science ®Google Scholar
• Tsujita K, Sugiyama S, Sumida H, et al. Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: the Multicenter Randomized Controlled PRECISE-IVUS Trial. J Am Coll Cardiol. 2015;66(5):495–507.
   PubMed Web of Science ®Google Scholar
• Roelandt JRTC, Serruys PW, Bom N, et al. Intravascular real-time, two-dimensional echocardiography. Int J Cardiac Imaging. 1989;4(1):63–67.
   PubMedGoogle Scholar
• Nissen SE, Yock P. Intravascular Ultrasound. Circulation. 2001;103(4):604–616.
   PubMedGoogle Scholar
• Lewis MA, Pascoal A, Keevil SF, et al. Selecting a CT scanner for cardiac imaging: the heart of the matter. Br J Radiol. 2016;89(1065):20160376.
   PubMedGoogle Scholar
• Hetterich H, Webber N, Willner M, et al. AHA classification of coronary and carotid atherosclerotic plaques by grating-based phase-contrast computed tomography. Eur Radiol. 2016;26(9):3223–3233.
   PubMedGoogle Scholar
• Kramer CM, Anderson JD. MRI of atherosclerosis: diagnosis and monitoring therapy. Expert Rev Cardiovasc Ther. 2007;5(1):69–80.
   PubMedGoogle Scholar
• Mintz GS, Garcia-Garcia H, Nicholls S, et al. Clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound regression/progression studies. EuroIntervention. 2011;6(9):1123–30, 9.
   PubMedGoogle Scholar
• Papadopoulou S-L, Neefjes LA, Garcia-Garcia HM, et al. Natural History of Coronary Atherosclerosis by Multislice Computed Tomography. JACC Cardiovasc Imaging. 2012;5(3_Supplement):S28–S37.
   PubMedGoogle Scholar
• Kini Annapoorna S, Vengrenyuk Y, Yoshimura T, et al. Fibrous Cap Thickness by Optical Coherence Tomography In Vivo. J Am Coll Cardiol. 2017;69(6):644–657.
   PubMedGoogle Scholar
• Endo A. A historical perspective on the discovery of statins. Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(5):484–493.
   PubMed Web of Science ®Google Scholar
• Brown G, Albers JJ, Fisher LD, et al. Regression of Coronary Artery Disease as a Result of Intensive Lipid-Lowering Therapy in Men with High Levels of Apolipoprotein B. N Engl J Med. 1990;323(19):1289–1298.
   PubMed Web of Science ®Google Scholar
• Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (Mars). Ann Intern Med. 1993;119(10):969–976.
   PubMedGoogle Scholar
• Waters D, Higginson L, Gladstone P, et al. Effects of cholesterol lowering on the progression of coronary atherosclerosis in women. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) substudy. Circulation. 1995;92(9):2404–2410.
   PubMedGoogle Scholar
• Jukema JW, Bruschke AVG, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91(10):2528–2540.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of Very High-Intensity Statin Therapy on Regression of Coronary AtherosclerosisThe ASTEROID Trial. JAMA. 2006;295(13):1556–1565.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078–2087.
   PubMed Web of Science ®Google Scholar
• Takayama T, Hiro T, Yamagishi M, et al. Effect of Rosuvastatin on Coronary Atheroma in Stable Coronary Artery Disease Multicenter Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese Subjects (COSMOS). Circ J. 2009;73(11):2110–2117.
   PubMed Web of Science ®Google Scholar
• Komukai K, Kubo T, Kitabata H, et al. Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study. J Am Coll Cardiol. 2014;64(21):2207–2217.
   PubMed Web of Science ®Google Scholar
• Nishiguchi T, Kubo T, Tanimoto T, et al. Effect of Early Pitavastatin Therapy on Coronary Fibrous-Cap Thickness Assessed by Optical Coherence Tomography in Patients With Acute Coronary Syndrome: the ESCORT Study. JACC Cardiovasc Imaging. 2018;11(6):829–838.
   PubMedGoogle Scholar
• Otaki Y, Tamarappoo B, Cadet SJ, et al. Decrease in LDL-C is associated with decrease in all components of noncalcified plaque on coronary CTA. Atherosclerosis. 2019;285:128–134.
   PubMedGoogle Scholar
• Hoffmann U, Lu MT, Olalere D, et al. Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): effects of pitavastatin on coronary artery disease and inflammatory biomarkers. Am Heart J. 2019;212:1–12.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387–2397.
   PubMed Web of Science ®Google Scholar
• Hougaard M, Hansen HS, Thayssen P, et al. Influence of ezetimibe in addition to high-dose atorvastatin therapy on plaque composition in patients with ST-segment elevation myocardial infarction assessed by serial: intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovasc Revasc Med. 2017;18(2):110–117.
   PubMedGoogle Scholar
• Ueda Y, Hiro T, Hirayama A, et al. Effect of Ezetimibe on Stabilization and Regression of Intracoronary Plaque - The ZIPANGU Study. Circ J. 2017;81(11):1611–1619.
   PubMedGoogle Scholar
• Nicholls SJ, Puri R, Anderson T, et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: the GLAGOV Randomized Clinical Trial. Jama. 2016;316(22):2373–2384.
   PubMed Web of Science ®Google Scholar
• Ako J, Hibi K, Tsujita K, et al. Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients With Acute Coronary Syndrome - The ODYSSEY J-IVUS Trial. Circ J. 2019;83(10):2025–2033.
   PubMed Web of Science ®Google Scholar
• Zanchin C, Koskinas KC, Ueki Y, et al. Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study-Rationale and design of the PACMAN-AMI trial. Am Heart J. 2021;238:33–44.
   PubMedGoogle Scholar
• Hirai K, Imamura S, Hirai A, et al. Effect of Evolocumab on Vulnerable Coronary Plaques: a Serial Coronary Computed Tomography Angiography Study. J Clin Med. 2020;9(10):3338.
   Google Scholar
• Bays HE, Tighe AP, Sadovsky R, et al. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther. 2008;6(3):391–409.
   PubMedGoogle Scholar
• Sperling LS, Nelson JR. History and future of omega-3 fatty acids in cardiovascular disease. Curr Med Res Opin. 2016;32(2):301–311.
   PubMed Web of Science ®Google Scholar
• Jump DB, Depner CM, Tripathy S. Omega-3 fatty acid supplementation and cardiovascular disease. J Lipid Res. 2012;53(12):2525–2545.
   PubMed Web of Science ®Google Scholar
• Ando K, Watanabe T, Daidoji H, et al. Combination Therapy of Eicosapentaenoic Acid and Pitavastatin for Coronary Plaque Regression Evaluated by Integrated Backscatter Intravascular Ultrasonography: a Randomized Controlled Trial. Circulation. 2015;132. DOI:https://doi.org/10.1161/CIRCULATIONAHA.115.015242
   Google Scholar
• Niki T, Wakatsuki T, Yamaguchi K, et al. Effects of the Addition of Eicosapentaenoic Acid to Strong Statin Therapy on Inflammatory Cytokines and Coronary Plaque Components Assessed by Integrated Backscatter Intravascular Ultrasound. Circ J. 2016;80(2):450–460.
   PubMed Web of Science ®Google Scholar
• Nagahara Y, Sarai M, Ito H, et al. The impact of eicosapentaenoic acid on prevention of plaque progression detected by coronary computed tomography angiography [abstract P5235]. Eur Heart J. 2016;37:1052.
   Google Scholar
• Budoff MJ, Muhlestein JB, Bhatt DL, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results. Cardiovasc Res. 2021;117(4):1070–1077.
   PubMedGoogle Scholar
• Lakshmanan S, Buckler A, Bhatt DL, et al. Abstract 15389: effect of Icosapent Ethyl on Changes in Coronary Plaque Characteristics at 9 Months in Patients With Elevated Triglycerides on Statin Therapy: insights From EVAPORATE. Circulation. 2020;142(Suppl_3):A15389–A15389.
   Google Scholar
• Kita Y, Watanabe M, Kamon D, et al. Effects of Fatty Acid Therapy in Addition to Strong Statin on Coronary Plaques in Acute Coronary Syndrome: an Optical Coherence Tomography Study. J Am Heart Assoc. 2020;9(16):e015593.
   PubMedGoogle Scholar
• Reiner Z. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Nutr Metab Cardiovasc Dis. 2013;23(9):799–807.
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089–2099.
   PubMed Web of Science ®Google Scholar
• Fayad ZA, Mani V, Woodward M, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet. 2011;378(9802):1547–1559.
   PubMed Web of Science ®Google Scholar
• Vaidya K, Arnott C, Martínez GJ, et al. Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome. JACC Cardiovasc Imaging. 2018;11(2_Part_2):305–316.
   PubMedGoogle Scholar
• Choi H, Uceda DE, Dey AK, et al. Treatment of Psoriasis With Biologic Therapy Is Associated With Improvement of Coronary Artery Plaque Lipid-Rich Necrotic Core: results From a Prospective, Observational Study. Circ Cardiovasc Imaging. 2020;13(9):e011199.
   PubMed Web of Science ®Google Scholar
• Karpouzas GA, Ormseth SR, Hernandez E, et al. Biologics May Prevent Cardiovascular Events in Rheumatoid Arthritis by Inhibiting Coronary Plaque Formation and Stabilizing High-Risk Lesions. Arthritis Rheumatol. 2020;72(9):1467–1475.
   PubMedGoogle Scholar
• Spanbroek R, Gräbner R, Lötzer K, et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci U S A. 2003;100(3):1238–1243.
   PubMedGoogle Scholar
• Matsumoto S, Ibrahim R, Grégoire JC, et al. Effect of treatment with 5-lipoxygenase inhibitor VIA −2291 (atreleuton) on coronary plaque progression: a serial CT angiography study. Clin Cardiol. 2017;40(4):210–215.
   PubMed Web of Science ®Google Scholar
• Ko YG, Choi SH, Chol Kang W, et al. Effects of combination therapy with cilostazol and probucol versus monotherapy with cilostazol on coronary plaque, lipid and biomarkers: SECURE study, a double-blind randomized controlled clinical trial. J Atheroscler Thromb. 2014;21(8):816–830.
   PubMedGoogle Scholar
• Lee DH, Chun EJ, Oh TJ, et al. Effect of cilostazol, a phosphodiesterase-3 inhibitor, on coronary artery stenosis and plaque characteristics in patients with type 2 diabetes: ESCAPE study. Diabetes Obes Metab. 2019;21(6):1409–1418.
   PubMedGoogle Scholar
• Elango K, Javaid A, Khetarpal BK, et al. The Effects of Warfarin and Direct Oral Anticoagulants on Systemic Vascular Calcification: a Review. Cells. 2021;10(4):773.
   PubMedGoogle Scholar
• Plank F, Beyer C, Friedrich G, et al. Influence of vitamin K antagonists and direct oral anticoagulation on coronary artery disease: a CTA analysis. Int J Cardiol. 2018;260:11–15.
   PubMedGoogle Scholar
• Win TT, Nakanishi R, Osawa K, et al. Apixaban versus warfarin in evaluation of progression of atherosclerotic and calcified plaques (prospective randomized trial). Am Heart J. 2019;212:129–133.
   PubMedGoogle Scholar
• Nicholls SJ, Tuzcu EM, Wolski K, et al. Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study. J Am Coll Cardiol. 2011;57(2):153–159.
   PubMedGoogle Scholar
• Patil HR, Al Badarin FJ, Al Shami HA, et al. Meta-Analysis of Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Risk in Type 2 Diabetes Mellitus. Am J Cardiol. 2012;110(6):826–833.
   PubMed Web of Science ®Google Scholar
• Monami M, Ahrén B, Dicembrini I, et al. Dipeptidyl peptidase‐4 inhibitors and cardiovascular risk: a meta‐analysis of randomized clinical trials. Diabetes Obesity Metab. 2013;15(2):112–120.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med. 2013;369(14):1317–1326.
   PubMed Web of Science ®Google Scholar
• White WB, Cannon CP, Heller SR, et al. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. N Engl J Med. 2013;369(14):1327–1335.
   PubMed Web of Science ®Google Scholar
• Nozue T, Takamura T, Fukui K, et al. Changes in coronary atherosclerosis, composition, and fractional flow reserve evaluated by coronary computed tomography angiography in patients with type 2 diabetes. Int J Cardiol Heart Vasc. 2018;19:46–51.
   PubMedGoogle Scholar
• Kataoka Y, Nicholls SJ, Andrews J, et al. Plaque microstructures during metformin therapy in type 2 diabetic subjects with coronary artery disease: optical coherence tomography analysis. Cardiovasc Diagn Ther. 2022;12(1):77–87.
   PubMedGoogle Scholar
• Scherer D, Kataoka Y, Pisaniello A, et al. Characteristics of plaque microstructures in diabetic patients receiving metformin: frequency domain optical coherence tomography analysis. Heart Lung Circ. 2015;24:S331.
   Google Scholar
• Institute of Medicine Committee on Assessing the Need for Clinical Trials of Testosterone Replacement, T. Testosterone and Aging: clinical Research Directions. Liverman CT, Blazer DG, Editors. Washington (DC): National Academies Press (US) Copyright 2004 by the National Academy of Sciences. All rights reserved; 2004.
   Google Scholar
• Barrett-Connor E, Khaw KT. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation. 1988;78(3):539–545.
   PubMedGoogle Scholar
• Smith GD, Ben-Shlomo Y, Beswick A, et al. Cortisol, testosterone, and coronary heart disease: prospective evidence from the Caerphilly study. Circulation. 2005;112(3):332–340.
   PubMed Web of Science ®Google Scholar
• Henzel J, KepKa C, Kruk C, et al. High-Risk Coronary Plaque Regression After Intensive Lifestyle Intervention in Nonobstructive Coronary Disease: a Randomized Study. JACC Cardiovasc Imaging. 2021;14(6):1192–1202.
   PubMed Web of Science ®Google Scholar
• Fang JC, Kinlay S, Beltrame J, et al. Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial. Lancet. 2002;359(9312):1108–1113.
   PubMed Web of Science ®Google Scholar
• Shaikh K, Kinninger A, Cherukuri L, et al. Aged garlic extract reduces low attenuation plaque in coronary arteries of patients with diabetes: a randomized, double-blind, placebo-controlled study. Exp Ther Med. 2020;19(2):1457–1461.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Hsu A, Wolski K, et al. Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J Am Coll Cardiol. 2010;55(21):2399–2407.
   PubMed Web of Science ®Google Scholar